

Evaluation of Frequency, Drug Resistance and Serotyping of *Streptococcus Pneumoniae* in Iran: A Systematic Review

M. Yousefi (PhD)¹, M. Mohammadi (MSc)², D. Afshar (PhD)³, A. Nazari-Alam (PhD)^{*4}

1. Infectious Diseases Research Center, Birjand University of Medical Sciences, Birjand, I.R.Iran

2. Department of Microbiology, Faculty of Medicine, Kashan University of Medical Sciences, Kashan, I.R.Iran

3. Department of Microbiology and Virology, Faculty of Medicine, Zanzan University of Medical Sciences, Zanzan, I.R.Iran

4. Infectious Diseases Research Center, Kashan University of Medical Sciences, Kashan, I.R.Iran

J Babol Univ Med Sci; 23; 2021; PP: 189-198

Received: Feb 11st 2020, Revised: Aug 9th 2020, Accepted: Aug 31st 2020.

ABSTRACT

BACKGROUND AND OBJECTIVE: *Streptococcus pneumoniae* is one of the main etiologies of meningitis, pneumonia, sinusitis, and middle ear infection associated with significant morbidity and mortality. This report aims to review and report the serotype distribution and antimicrobial resistance patterns and determine the frequency of *S. pneumoniae* in Iran.

METHODS: A systematic literature review of the literature published from January 1990 to August 2020 was performed to identify articles that have been published in Google Scholar, Scopus, PubMed, SID, IranMedex, and Magiran databases that describe the serotype distribution, antimicrobial resistance patterns and frequency of *S. pneumoniae* in Iran. The search terms were "Streptococcus pneumoniae, Antibiotic resistance, Serotyping, Systematic review, and Iran". The exclusion criteria were review articles or case reports, reports only emphasizing on serogroups rather than serotypes, and having isolates fewer than 10.

FINDINGS: Of 56 reports, 33 publications that met our inclusion criteria were selected for data extraction and analysis. The frequency of *S. pneumoniae* in patients and carriers was estimated at 1.5% and 20%, respectively. Highest levels of resistance were against co-trimoxazole followed by penicillin, and erythromycin. The most common serotypes were 23F followed by 19F, 6A/B, 19A, and 18C.

CONCLUSION: Based on the results of this study, the inappropriate use of antibiotics and the subsequent spread of resistant pneumococcal isolates in our country is worrisome.

KEY WORDS: *Streptococcus Pneumoniae*, Antibiotic Resistance, Serotyping, Systematic Review, Iran.

Please cite this article as follows:

Yousefi M, Mohammadi M, Afshar D, Nazari-Alam A. Evaluation of Frequency, Drug Resistance and Serotyping of *Streptococcus Pneumoniae* in Iran: A Systematic Review. J Babol Univ Med Sci. 2021; 23: 189-98.

*Corresponding Author: A. Nazari-Alam (PhD)

Address: Infectious Diseases Research Center, Kashan University of Medical Sciences, Kashan, I.R.Iran

Tel: +98 31 55541112

E-mail: : nazarialam-a@kaums.ac.ir

Introduction

Streptococcus pneumoniae (pneumococcus) is a gram-positive bacterium. These types of microorganisms can be part of the natural flora of the nasopharynx in humans, and especially in children (1). This colonized bacterium is not dangerous, but it is able to migrate to other parts of the body, such as the ear, lungs, blood, and cerebrospinal fluid, and cause disruption in these organs (2). In addition, it may cause chronic infections such as pneumonia, meningitis, sinusitis, and otitis media in carriers. According to the World Health Organization (WHO), one million children die due to pneumococcal infections in the world every year (3, 4).

The colonization of this bacterium in the carriers plays an important role in the development of infection in the community (5). The *S. pneumoniae* is the main cause of a wide range of serious invasive diseases such as sepsis, bacteremia, and meningitis (6). These infectious diseases are causative of the life-threatening morbidity and mortality in pediatric patients and adults worldwide (7, 8). For the treatment of pneumococcal infections, the antibiotics of the group of macrolides, beta-lactams, fluoroquinolones, co-trimoxazole, and vancomycin have been frequently used (9, 10); however, during the past decades, drug resistance has increased and antibiotics biotypes become a further challenge (11, 12).

Vaccination is recommended to fight against this pathogen and control it (13). Vaccination greatly reduces the incidence of infections caused by this bacterium. The vaccines used today are multivalent conjugated vaccines (14). Generally, this bacterium includes over 93 serotypes. For the first time in 2000, a seven-valent pneumococcal conjugate vaccine (PCV7) has been used (13). These conjugate vaccines contain the most common serotypes that are the cause of pneumococcal disease. These serotypes include 4, 6B, 9V, 14, 18C, 19F, and 23F. However, after using the vaccine in the community for a while, it became clear that the vaccine did not have the desired efficacy. To overcome this problem, PCV10 and PCV13 were replaced. In addition to these strains, vaccines include 7 F/A, 19A, 1, 3, 5, and 6 A/C. But after using these vaccines, their impact was reduced again (13).

To compensate for this deficiency, the pneumococcal polysaccharide vaccine (PPSV23) was introduced (15). To increase the effectiveness of this type of vaccine in different societies, there is a need for relevant information, including the frequency of this pathogen in each community, the type of

circulating serotypes in the community, and antibiotic susceptibility testing. Regarding this fact, various studies have been conducted about this issue in Iran; however, there is high inconsistency between the results. So far, pneumococcus vaccine has not been embraced in the Expanded Program on Immunization (16) in Iran and is advised only for at-risk groups.

In Iran, information about serotypes is rarely available due to the low level of positive reports, which is due to the improper use of antibiotics and the problems of culturing the bacteria themselves. The main purpose of designing this systematic review is to determine pneumococcal serotypes, antibiotic resistance and its frequency in Iran. The specific objectives of this review are to review the distribution of serotypes, patterns of antibiotic resistance of *S. pneumoniae* in Iran and to fill existing information gaps and provide basic and important information for pneumococcal vaccination policies.

Methods

Study design and search method: We have been done a systematic literature review of reports published from January 1990 to August 2020 about circulating pneumococcal serotypes in Iran by identifying articles that have been published in Google Scholar, Scopus, PubMed, SID, IranMedex, and Magiran databases that describe the serotype distribution, antimicrobial resistance patterns and frequency of *S. pneumoniae* in Iran. The search terms were "Streptococcus pneumoniae, Antibiotic resistance, Serotyping, Systematic review, and Iran". Articles that were published in Persian or English were reviewed. The study was registered with the ethics code IR.KAUMS.REC.1399.024

Inclusion and exclusion criteria: We considered observational studies (prospective, retrospective, analytical and descriptive) reporting data on frequency, serotypes distribution and antimicrobial resistance patterns of *S. pneumoniae* serotypes obtained from clinical samples (e.g., blood, CSF, pleural fluid, joint or peritoneal fluid, ear, eye, nasopharynx, or tracheal aspirates in clinical cases, or nasopharyngeal specimens in carriers) in Iran. The exclusion criteria were the relevant studies not carried out in Iran, studies in which type of patients and their age was unclear, studies whose sample size included less than 10 isolates, review articles, systematic reviews, case reports, and articles that were only available in abstract form.

Data extraction: Our search results were combined by EndNote software, and duplicate documents were removed. Titles and abstracts were reviewed in terms of incompetence criteria and items that did not meet the target criteria were excluded from the study. The full texts of reports were read carefully, and organized pattern tables were built in Microsoft Excel spreadsheet and used to record the extracted data for the following variables: specified sample size, the specificity of the statistical population, number of isolates greater than 10, date of the study, date of publication, place of study, prevalence, antibiotics susceptibility results (penicillin, erythromycin, vancomycin, chloramphenicol, gentamicin, cefotaxime, ceftriaxone, tetracycline, rifampin, co-trimoxazole, ciprofloxacin, and ampicillin) and serotyping. Four researchers on the team freely performed literature review and explored all titles and abstracts of the articles. We assessed the quality of the articles by the adapted form of the Newcastle-Ottawa cohort scale for cross-sectional studies.

Data analysis: Analysis of the extracted data was performed using the Microsoft Excel spreadsheet program. The collected data were categorized into three areas: "Streptococcus pneumoniae prevalence", "Antibiotic resistance" and "Pneumococcal serotypes". The percentage of the serotypes was computed by dividing the number of isolates for each serotype by the total number of isolates included in all the reports. The frequency of antimicrobial resistance was defined as the percentage of isolates that were divided by the total number of isolates tested for resistance against the above specific antimicrobial agent.

Results

We screened 56 articles in our preliminary search, of which 33 studies fulfilled inclusion criteria and were included in the final analysis (Fig. 1) Among them, 23 articles that did not meet our criteria were excluded from the study (Fig. 1).

The frequency of *S. pneumoniae* in carriers: The first studies were from 1998 to 2005 which examined the frequency of bacteria in 2629 subjects and 315 (12%) cases were reported in three studies (17-19). In four studies conducted from 2005 to 2012, 973 (24.3%) of the 4008 studied children were pneumococcus carriers (20-23). Ten studies were conducted from 2013 to 2020 and 240 (24.1%) subjects of 1450 studied people were pneumococcus carriers (16, 24-32). Based on all the

mentioned studies, the average prevalence of Iranian carriers was estimated at 20%.




Figure 1. Flowchart of search method and selection of articles

Frequency of *S. pneumoniae* in patients: Two studies were conducted during the years 1997-2003, in which 57 pneumococcus isolates were obtained from 732 clinical specimens. The frequency of this bacterium was 7.79% (33, 34). In studies conducted from 2003 to 2013, 101 isolates of pneumococcus were obtained from 18519 clinical samples, and in other words, the frequency of pneumococcus was 0.55% (35-37). In other surveys, 1160 different clinical samples were collected from patients from 2013 to 2016 and were investigated for the presence of *S. pneumoniae*. In those studies, 148 (12.76%) bacterial isolates of pneumococcus were identified (12, 38, 39). Based on results of the mentioned studies, the average frequency of pneumococcus in Iranian patients was estimated at 1.5%.

Antibiotic Resistance: Of studies included in our analysis, the antibiogram test has been done in 31 studies (7, 12, 16, 18-24, 27-29, 32-37, 39-50). These antibiotics were penicillin, erythromycin, vancomycin, chloramphenicol, gentamicin, cefotaxime, ceftriaxone, tetracycline, rifampin, co-trimoxazole, ciprofloxacin,

and ampicillin. Based on these results, on average, isolates were most resistant to co-trimoxazole, penicillin, and erythromycin. In these studies, the antibiotics with the least resistance were vancomycin, cefotaxime, and ceftriaxone, respectively. The complete results of the antibiogram extracted from 26 articles are given in Table 1.

Determination of pneumococcal serotypes: Of 32 articles reviewed in our study, only 9 articles provided information about prevalent serotypes in Iran. Based on

these studies, different serotypes were found in Iran: 1, 2, 3, 4, 6, 6A/B, 7F, 8, 9, 9V, 10A, 11, 11A, 13, 14, 15, 15A, 15C, 17, 18C, 19, 19A, 19B, 19C, 19F, 20, 21, 22F, 23, 23A, 23F, 29, 31, 33, 34, 35A, 35B, and 37 (16, 20, 23, 24, 26, 32, 49, 51, 52). Among serotypes mentioned above, the most common serotypes were 23F, 19F, 6A/B, 19A, and 18C. In most studies, there were serotypes that were non-typable which in some cases were up to 26% of all strains.

Table 1. Antimicrobial resistance pattern of *S. pneumoniae* isolates

First author	Year	Province	Sample size	Antibiotic resistance (%)											
				PEN	ERY	VAN	CAM	GEN	CTX	CRO	TCN	RPM	SXT	CIP	AMP
Khajeh	1998-1999	Mashhad	90	38	-	-	-	-	-	-	-	-	-	-	-
Khotayi	1997-2000	Tehran	46	17	-	-	-	-	-	-	-	-	-	-	-
Yousefi Mashouf	1998-2000	Hamadan	11	-	-	-	36	0	-	0	-	-	27	-	63
Oskouei	1998-2000	Tehran	130	-	8	0	22	-	-	-	36	-	44	-	0
Jahanmehr	1999-2001	Tehran	66	18	-	0	-	-	-	-	-	-	-	-	7.5
Rajabi	2000	Tehran	66	28.8	-	0	-	-	-	-	-	-	-	-	7.5
Oskouei	2000-2008	Tehran	54	26	16.6	-	-	-	3.7	-	18.5	-	52	-	-
Behnaz	2002	Yazd	75	50	62.5	-	-	-	-	-	30.6	-	62.5	4.2	-
Rezaeizadeh	1998-2008	Tehran	30	56.7	20	0	20	76.7	-	-	-	-	63.3	-	20
Haghi Ashtiani	2001-2011	Tehran	194	46	51	0	30	63	13	12	-	-	72	-	24
Zargarizadeh	2002-2003	Tehran	50	44	26	0	16	-	8	6	20	2	65	-	-
Abdinia	2003-2013	Tabriz	44	37.8	16.2	0	5.4	22.8	8.1	10.8	-	2.7	32.4	8	-
Fahimzad	2004-2006	Tehran	20	35	-	0	10	-	-	-	-	10	60	-	-
Bakhshaei	2005-2006	Mashhad	102	48	43.1	-	-	-	-	-	-	-	80.4	-	-
Shishegar	2007-2008	Shiraz	12	-	10	-	-	-	20	-	-	-	100	0	50
Bokaeian	2008-2009	Zahedan	136	9.5	18	0	8	-	2.2	3.6	9.5	-	-	1.4	-
Sanaei Dashti	2008-2009	Tehran	573	9.2	-	1.5	6	-	3	4.5	66	0	11.8	1.5	-
Kargar	2010-2011	Shiraz	50	60	18	-	0	0	50	-	10	-	48	-	56
Soltan Dalal	2012	Tehran	15	80	65	53	53	0	-	-	0	-	-	-	65
Mirzaei	2011-2012	Kashan	291	-	3.4	0	-	-	-	-	25.5	0	-	-	-
Sabory	2012	Kermanshah	83	-	-	-	-	-	-	31	-	41	4	-	-
Tabatabaei	2012-2015	Tehran	73	20.5	83.6	7	-	-	42.5	31.5	-	-	15	-	-
Gharailoo	2013-2014	Sistan-Baluchestan	74	-	56	0	16	46	0	-	61	-	93	-	-
Houri	2014	Tehran	53	19.1	71.4	0	-	-	4.7	9.5	66.9	-	57.1	-	-

First author	Year	Province	Sample size	Antibiotic resistance (%)											
				PEN	ERY	VAN	CAM	GEN	CTX	CRO	TCN	RPM	SXT	CIP	AMP
Najafi Mosleh	2015	Hamedan	55	-	25.5	0	-	-	-	-	-	-	-	11	-
Mousavi	2014-2015	Tehran	76	-	86	-	-	94	-	-	5	0	-	-	-
Mohammadi Gharibani	2015	Ardabil	43	95.34	74.4	-	16.3	-	-	-	-	-	81.4	-	-
Ahmadi	2016	Tehran	100	22	59	-	23	-	-	-	57	-	92	3	-
Talebi	2013-2015	Tehran	161	58	60	-	59	-	-	-	75	-	94	-	-
Emaneini	2016-2017	Tehran	44	16	73	-	14	-	-	-	66	-	86	-	-
Ghahfarokhi	2015-2017	Tehran	80	8.7	55	-	18	-	-	-	20	-	63	-	-
	And			27.5	68		20				15		80		
	2018-2019														

Pen: penicillin, ERY: erythromycin, VAN: vancomycin, CAM: chloramphenicol, GEN: gentamicin, CTX: cefotaxime, CRO: ceftriaxone, TCN: tetracycline, RPM: rifampin, SXT: co-trimoxazole, CIP: ciprofloxacin, AMP: ampicillin

Discussion

In this review, we have shown that the most frequent serotypes obtained from Iranian Patients were 23F followed by 19F, 6A/B, 19A, and 18C. The main findings of our report are the frequency of *S. pneumoniae* in patients and carriers, which were estimated at 1.5% and 20%, respectively. The highest resistance rates were against co-trimoxazole followed by penicillin, and erythromycin. In other parts of the world, the most common serotypes are 14, 1, 4, 6 A / B, 3, and 8 (53). The frequency of serotypes in Iran is very different from other parts of the world (2, 8), but is in agreement with a systematic review by Singh et al. in 2017 in India, according to which, the serotypes 14, 1, 19F, 6B, 5, 6A, 9V, and 23F were the most common ones (54).

The prevalence of these serotypes may increase in cases where blood cultures are performed exclusively for hospitalized patients (55). Thus, infectious serotypes appear to cause serious infectious diseases that require hospitalization (4, 5). Polyvalent vaccines (seven, ten, thirteen, twenty-three) are used to prevent pneumococcus (13, 56). The use of this type of vaccine should be based on the type of serotype circulating in the community, but in Iran, it is recommended to provide a comprehensive study on the frequency of pneumococcal serotypes in all regions of Iran. In agreement with a report by Azarsa et al. in 2015 in Tehran on 560 clinical samples, the most prevalent serotypes in penicillin non-susceptible *S. pneumoniae*

isolates were 23F, 19F, 14, 3 and 9V (26) and in a report by Abdoli et al. in 2020 in Bojnurd, of 106 cases of *S. pneumoniae*, serotypes 23F, 19F, 19A, 1, 14 were the most prevalent (25) and similar to in our report, the major serotypes were 23F and 19F. In other current reports, a similarity was observed in serotype distribution in Iran. In a report by Ahmadi et al. in 2019, the most common serotypes were 14, 19F, 23F (28). In a report by Talebi et al. in 2019, the most frequent serotypes among the penicillin non-susceptible *S. pneumoniae* were 14, 23F, and 19F (50) and in a report by Ghahfarokhi et al. in 2020 in Tehran, the most common serotypes were 23F, 14, 3 19F, and 19A (32).

All of the previous reports revealed that major serotypes in Iran in recent years are 23F and 19F which can be used in vaccine preparation for our social situations. Opposite to the report by Rafiei Tabatabaei et al. in 2019, in which the identified serotypes were the serotypes 1, 4, 6A/B, 7F, 9V, 11A, 14, 15A, 19A, 19F, and 23F (2), our major serotype was 23F. Genetic mutations can change in specific areas, and the causes must be evaluated. A study by Beheshti et al. in 2020 demonstrated that all of the penicillin-resistant isolates were multidrug-resistant (MDR) and the most common capsule types detected in 64% of the pneumococcal isolates were 6A/B, 19A, 15A, 23F (16). One can presume that the isolated MDR can be our major problem in Iran because this result was very similar to our results. By comparing studies performed in Iran and

studies in other parts of the world (1, 4, 5, 55, 57-59), it can be seen that there is a significant difference with the prevalence of pneumococcal meningitis in Iran, which is low. Thus, one can say that the main cause of bacterial meningitis in Iran is a microorganism other than pneumococcus. To prove this claim, it is necessary to make a comprehensive study in this regard. The frequency of pneumonia caused by this bacterium is reported to be 25% and 28% in the United States and Germany, respectively (60, 61). In a study by Edmond et al., pneumococcus prevalence was reported to be 15.5% (62).

Contrary to these reports, the frequency of *S. pneumoniae* in patients was estimated at 1.5% in other regions of Iran, which is very low in comparison with other countries. The frequency of *S. pneumoniae* in the Netherlands, Spain, and China was reported to be 22%, 36%, and 16.6%, respectively (58, 63, 64), which is very higher in comparison with our report indicating 1.5% prevalence in Iran. On the other hand, this is in agreement with the study of Ahangarzadeh Rezaee et al. which was performed on children with cancer, and showed that 2% of patients had pneumococcal infection (65). In this study, it has been shown that pneumococcal bacteria can be considered as a life-threatening infectious agent in cancer patients.

The second issue in pneumococcal infections is the status of carriers and one of the limitations of these studies was that the age of the evaluated carriers was not the same. The average number of pneumococcal carriers in the world is between 3% and 18% (53) but the frequency of *S. pneumoniae* in carriers was estimated at 20%. Based on these studies, the number of pneumococcal carriers in different regions of Iran is higher than the global average. Factors involved in this phenomenon include non-observance of health care and lack of regular vaccination in the exposed age groups. Scientific documents on *S. pneumoniae* antibiotic resistance at global level have greatly increased in recent years. Scientists and physicians need to differentiate antibiotic resistance patterns for meningitis and non-meningitis isolates. According to the results of studies, the highest drug resistance of pneumococcus in Iran is related to co-trimoxazole (maximum range), erythromycin and penicillin, respectively. In Africa, the highest resistance is related to co-trimoxazole and tetracycline (57).

In Asia, the highest resistance is related to erythromycin and penicillin (66), which is somewhat similar to the studies conducted in Iran. Studies on

antibiotic susceptibility of pneumococcus are carried out periodically and regularly in most Asian countries (59, 66, 67), but there are few studies available in Iran. One of them is the study of Rafiei Tabatabaei et al. in 2017 in Tehran. In their study, among 73 *S. pneumoniae* isolates, antibiotic susceptibilities were 95.9% to ofloxacin, 93% to vancomycin and 78% to penicillin, revealing an increase in *S. pneumoniae* isolates that were resistant to conventional drugs in the course of treatment (39). This is in agreement with the study of Mohammadi Gharibani in 2019 in Ardabil, according to which 74.4 % of the isolates were resistant to erythromycin, 95.3% to penicillin, 81.3 % to co-trimoxazole (27).

We can claim that the current therapeutic strategies are not suitable in Iran and they need a change. The vancomycin resistance was very rare in our results but in a report by Nazari Alam et al. in 2017 in Tehran, 5 *S. pneumoniae* isolates were found to be resistant to vancomycin. Their results demonstrated that an alarming rate of vancomycin-resistant pneumococci may result from the uncontrolled use of vancomycin and self-medication (8).

Considering the existing gap, it is necessary to conduct regular studies under the supervision of a single unit in Iran and we must consider correct management of the antibiotics, reduction in the cost of treatment and timely treatment of patients with the pneumococcal disease based on the obtained information. In conclusion, although regular studies have not been performed on pneumococcus in different regions in Iran, the frequency of carriers and types of serotypes can be estimated based on our systematic review data and based on that strategy, the vaccination strategy can be revised and fundamental changes can be made. In addition, while considering drug resistance in pneumococcal isolates, proper treatment program should be performed for pneumococcal patients. The inappropriate use of antibiotics and the spread of resistant strains in the community have led to increased drug resistance of pneumococci, which is worrying in the future; to solve this problem, it is necessary to prepare and introduce an appropriate antibiotic prescription for pneumococcus.

Acknowledgment

We express our thanks to Vice Chancellor for Research and Technology of Kashan University of medical sciences for accompanying us in this research.

References

1. Feldman C, Anderson R. Recent advances in the epidemiology and prevention of *Streptococcus pneumoniae* infections. *F1000Res*. 2020;9:F1000 Faculty Rev-338.
2. Rafiei Tabatabaei S, Fallah F, Afshar D, Nazari Alam A. Molecular identification and detection of *Streptococcus pneumoniae* serotypes isolated from selected hospitals in Tehran using multiplex PCR method. *J Babol Univ Med Sci*. 2019;21(1):46-52. [In Persian]
3. Anthony L, Meehan A, Amos B, Mtove G, Mjema J, Malahiyo R, et al. Nasopharyngeal carriage of *Streptococcus pneumoniae*: prevalence and risk factors in HIV-positive children in Tanzania. *Int J Infect Dis*. 2012;16(10):e753-7.
4. Suaya JA, Mendes RE, Sings HL, Arguedas A, Reinert R-R, Jodar L, et al. *Streptococcus pneumoniae* Serotype Distribution and Antimicrobial Nonsusceptibility Trends Among Adults with Pneumonia in the United States, 2009–2017. *J Infect*. 2020;81(4):557-66.
5. Li M-C, Wang Y, Zhang H, Liu Y, Chen X-J, Yang H-W, et al. Serotype distribution and clinical characteristics associated with *Streptococcus pneumoniae* among Chinese children and adults with invasive pneumococcal disease: a multicenter observational study. *Hum Vaccin Immunother*. 2021;17(1):146-56.
6. Kim L, McGee L, Tomczyk S, Beall B. Biological and epidemiological features of antibiotic-resistant *Streptococcus pneumoniae* in pre-and post-conjugate vaccine eras: a United States perspective. *Clin Microbiol Rev*. 2016;29(3):525-52.
7. Khajeh Karamodini M, Sarvghad M, Alamian Samak khah S, Jahan Shahi A. Determination of the minimum inhibitory concentration of penicillin compared to pneumococcus. *Med J Mashhad Univ Med Sci*. 2001;44(73):84-90. [In Persian] Available from: <https://www.sid.ir/FA/JOURNAL/ViewPaper.aspx?id=14007>
8. Nazari Alam A, Tabatabaei SR, Hashemi A, Yousefi M, Hoseini Alfatemi SM. Characterization of 5 Episodes of Vancomycin Nonsusceptible *Streptococcus pneumoniae* From Clinical Isolates in Tehran, Iran. *Archives of Clinical Infectious Diseases*. 2017;12(2): e57285.
9. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. *Clin Infect Dis*. 2007;44(Suppl 2):S27-72.
10. Al-Tawfiq JA, Momattin H, Hinedi K. Empiric antibiotic therapy in the treatment of community-acquired pneumonia in a general hospital in Saudi Arabia. *J Glob Infect Dis*. 2019;11(2):69-72.
11. Koliou MG, Andreou K, Lamnisos D, Lavranos G, Iakovides P, Economou C, et al. Risk factors for carriage of *Streptococcus pneumoniae* in children. *BMC Pediatr*. 2018;18(1):144.
12. Mosleh MN, Gharibi M, Alikhani MY, Saidijam M, Vakhshiteh F. Antimicrobial susceptibility and analysis of macrolide resistance genes in *Streptococcus pneumoniae* isolated in Hamadan. *Iran J Basic Med Sci*. 2014;17(8):595-9.
13. Masomian M, Ahmad Z, Ti Gew L, Poh CL. Development of next generation *Streptococcus pneumoniae* vaccines conferring broad protection. *Vaccines (Basel)*. 2020;8(1):132.
14. Rinta-Kokko H, Palmu AA, Auranen K, Nuorti JP, Toropainen M, Siira L, et al. Long-term impact of 10-valent pneumococcal conjugate vaccination on invasive pneumococcal disease among children in Finland. *Vaccine*. 2018;36(15):1934-40.
15. Schiffner-Rohe J, Witt A, Hemmerling J, von Eiff C, Leverkus F-W. Efficacy of PPV23 in preventing pneumococcal pneumonia in adults at increased risk—a systematic review and meta-analysis. *PLoS One*. 2016 Jan 13;11(1):e0146338.
16. Beheshti M, Jabalameli F, Feizabadi MM, Bonakdar Hahsemi, F, Beigverdi R, Emaneini M. Molecular characterization, antibiotic resistance pattern and capsular types of invasive *Streptococcus pneumoniae* isolated from clinical samples in Tehran, Iran. *BMC Microbiol*. 2020;20:167.
17. Ghaemi EE, Fazeli MR, Tabaraei AJ, Vakili MA. The prevalence of pneumococci throat carrier in healthy school children in Gorgan. *J Urmia Univ Med Sci*. 2002;13(1):16-24. [In Persian]
18. Behnaz F, Firousabadi L, Babaei-Zadeh A, Mohammad-Zadeh M. Prevalence of Pharyngeal Pneumococcal Carriers and Susceptibility Patterns among Children of Day Care Centers in Yazd District, Iran. *J Shahid Sadoughi Univ Med Sci*. 2004;12(1):65-9. [In Persian]

19. Bakhshaei M, Ghazvini K, Naderi HR, Zamanian A, Haghighi J, Boghrabadian M. The prevalence of nasopharyngeal streptococcal pneumonia carriers in Mashhad day care children and their antibiotic resistance pattern. *Iran J Otorhinolaryngol*. 2006;18(3):119-26. [In Persian]
20. Sanaei Dashti A, Abdinia B, Karimi A. Nasopharyngeal carrier rate of *Streptococcus pneumoniae* in children: serotype distribution and antimicrobial resistance. *Arch Iran Med*. 2012;15(8):500-3.
21. Mirzaee H, Moniri R, Piroozmand A, Valipour M, Rezaei M, Yasini M, et al. Evaluating the prevalence of pneumococcal nasopharyngeal carriers and the related risk factors among students in Kashan. *Feyz (J Kashan Univ Med Sci)*. 2014;17(6):597-601. [In Persian]
22. Sabory T, Ghadiri K, Abiri R, Elahi A, Poormohammadi Sh, Gharib AR. Incidence of nasopharyngeal carriers of streptococcus pneumoniae and antibiotic resistance in the children in Kermanshah 2012. *J Nurs Educ*. 2016;4(4):90-7. [In Persian]
23. Bokaeian M, Khazaei HA, Javadimehr M. Nasopharyngeal Carriage, Antibiotic Resistance and Serotype Distribution of *Streptococcus Pneumoniae* among Healthy Adolescents in Zahedan. *Iran Red Crescent Med J*. 2011;13(5):328-33.
24. Gharailoo Z, Mousavi SF, Halvani N, Feizabadi MM. Antimicrobial Resistant Pattern and Capsular Typing of *Streptococcus Pneumoniae* Isolated from Children in Sistan -Baluchestan. *Maedica (Bucur)*. 2016;11(3):203-7. Available from: <https://pubmed.ncbi.nlm.nih.gov/28694854/>
25. Abdoli S, Safamanesh S, Khosrojerdi M, Azimian A. Molecular Detection and Serotyping of *Streptococcus Pneumoniae* in Children with Suspected Meningitis in Northeast Iran. *Iran J Med Sci*. 2020;45(2):125-33.
26. Azarsa M, Moghadam SO, Rahbar M, Baseri Z, Pourmand MR. Molecular serotyping and genotyping of penicillin non-susceptible pneumococci: the introduction of new sequence types, Tehran, Iran. *New Microb New Infect*. 2019;32:100597.
27. Mohammadi Gharibani K, Azami A, Parvizi M, Khademi F, Mousavi SF, Arzanlou M. High Frequency of Macrolide-Resistant *Streptococcus pneumoniae* Colonization in Respiratory Tract of Healthy Children in Ardabil, Iran. *Tanaffos*. 2019;18(2):118-25.
28. Ahmadi A, Yaghoubi S, Irajian G. Molecular analysis of PBP1A in *Streptococcus pneumoniae* isolated from clinical and normal flora samples in Tehran, Iran: a multicenter study. *Microb Drug Resist*. 2019;25(1):39-46.
29. Mousavi SF, Mirzaei B, Shaghaghi B, Jalali P, Setayesh T, Moosavi SH. Phenotypic and genotypic features of first biofilm forming nasopharyngeal colonized *Streptococcus pneumoniae* isolates. *Iran J Microbiol*. 2017;9(4):200-7.
30. Gholamhosseini-Moghaddam T, Rad M, Mousavi SF, Ghazvini K. Detection of *lytA*, *pspC*, and *rrgA* genes in *Streptococcus pneumoniae* isolated from healthy children. *Iran J Microbiol*. 2015;7(3):156-60.
31. Moein Jahromi F, Kargar M, Doosti A, Mohammadalipour Z. Evaluation of Prevalence of *S. pneumoniae* pharyngeal carriers under 5 years of age by *lytA* gene detection. *Med Lab J*. 2016;10(6):1-6.
32. Ghahfarokhi SH, Mosadegh M, Ahmadi A, Pourmand MR, Azarsa M, Rahbar M, et al. Serotype Distribution and Antibiotic Susceptibility of *Streptococcus pneumoniae* Isolates in Tehran, Iran: A Surveillance Study. *Infect Drug Resist*. 2020;13:333-40.
33. Khotayi Q, Ashtiani MT, Makki N, Shekarabi D. Pneumococcal nasopharyngeal colonization during the first days of antibiotic treatment in pediatric patients. *Iran J Pediatr*. 2002;12(3):45-8. [In Persian]
34. Yosefi-Mashouf R, Hashemi SH, Shams S. Study of bacterial agents of meningitis in children and detection of antibiogram patterns in Hamadan. *Yafte*. 2004;5(2):31-9. [In Persian]
35. Rezaeizadeh G, Pourakbari B, Ashtiani MH, Asgari F, Mahmoudi S, Mamishi S. Antimicrobial susceptibility of bacteria isolated from cerebrospinal fluids in an Iranian referral pediatric center, 1998-2008. *Maedica (Bucur)*. 2012;7(2):131-7.
36. Shishegar M, Faramarzi A, Kazemi T, Bayat A, Motamedifar M. Polymerase chain reaction, bacteriologic detection and antibiogram of bacteria isolated from otitis media with effusion in children, Shiraz, Iran. *Iran J Med Sci*. 2011;36(4):273-80.

37. Soltan Dallal MM, Jabari H, Rahimi Forushani A, Heidarzadeh S, Afrogh P, Sharifi Yazdi MK. Frequency and Resistance Patterns of *Streptococcus Pneumoniae* in Acute Otitis Media. *J Mazandaran Univ Med Sci*. 2013;23(98):28-35. [In Persian]
38. Mohsenpoor M, Mehrabi Tavana A, Ataee R, Ranjbar R, Mirnejad R. Isolation and Identification of *Streptococcus pneumoniae* from Admitted Patients in Tehran Hospitals in during 2013-2015. *Iran J Med Microbiol*. 2017;11(2):9-16. [In Persian]
39. Rafiei Tabatabaei S, Rahbar M, Nazari Alam A, Fallah F, Hashemi A, Yousefi M, et al. Detection of *pbp2b* gene and antimicrobial susceptibility pattern of *Streptococcus pneumoniae* isolates in Tehran hospitals, Iran. *Arch Pediatr Infect Dis*. 2017;5(1):e38891.
40. Oskoui M, Feizabadi M-M, Amirkhani A. Drug susceptibility of *Streptococcus pneumoniae* strains isolated in Tehran, Iran. *Arch Iranian Med*. 2003;6(3):192-5.
41. Jahanmehr SAH, Rajabi A, Soltani Radd M, Behzadian Nejad Gh. The resistance of *Streptococcus pneumoniae* against penicillin and other antibiotics. *Act Med Iran*. 2004;42(3):223-7.
42. Rajabi A, Soltani-Rad M, Behzadian Nejad G. Evaluation of antibiotic resistance of *Streptococcus pneumoniae* and determination MIC and MBC of selective antibiotics. *Hakim Health Sys Res*. 2000;3(4):316-21. [In Persian] Available from: <https://www.sid.ir/fa/Journal/ViewPaper.aspx?id=25452>
43. Oskoui M, Nobari S, Rahmati Ghezelgeh F, Shaghaghi B, Amirmozafari N. Molecular characterization of PBP2b in clinical isolates of *Streptococcus pneumoniae*. *Iran J Med Microbiol*. 2010;4(1 And 2):9-16. [In Persian]
44. Haghi Ashtiani MT, Sadeghian M, Nikmanesh B, Pourakbari B, Mahmoudi S, Mamishi S. Antimicrobial susceptibility trends among *Streptococcus pneumoniae* over an 11-year period in an Iranian referral children Hospital. *Iran J Microbiol*. 2014;6(6):382-6.
45. Zargarizadeh A, Shirazian J, Zohrabi A. Evaluation of drug resistance of *Streptococcus pneumoniae* isolated from spinal fluid and sputum in meningitis and pneumonia patients in Tehran hospitals in 2001-2002. *Pajoothane*. 2004;9(1):9-15. [In Persian] Available from: <http://pajoothane.sbmu.ac.ir/article-1-155-fa.html>
46. Abdinia B, Ahangarzadeh Rezaee M, Abdoli Oskouie S. Etiology and antimicrobial resistance patterns of acute bacterial meningitis in children: a 10-year referral hospital-based study in northwest iran. *Iran Red Crescent Med J*. 2014;16(7):e17616.
47. Fahimzad AR, Mamaishi S, Noorbakhsh S, Siadati A, Hashemi FB, Tabatabaei SR, et al. Study Of Antibiotics Resistance In Pediatric Acute Bacterial Meningitis With E-Test Method. *Iran J Pediatr*. 2006;16(2):149-56. [In Persian]
48. Kargar M, Baghernejad M, Ghorbani Dalini S. The Role of *pbp1a*, *pbp2b* and *pbp2x* Genes in Penicillin Resistance in *Streptococcus pneumoniae* Strains Isolated from ICUs. *J Isfahan Med School*. 2012;30(175):1-8. [In Persian]
49. Houri H, Rafiei Tabatabaei S, Saei Y, Fallah F, Rahbar M, Karimi A. Distribution of capsular types and drug resistance patterns of invasive pediatric *Streptococcus pneumoniae* isolates in Teheran, Iran. *Int J Infect Dis*. 2017;57:21-6.
50. Talebi M, Sadeghi J, Ahmadi A, Lohrasbi V, Owlia P, Pourshafie MR. High Rate of Serotype Switching and Genetic Variations Indicates Widespread Recombination Between Clinical and Commensal Penicillin-Nonsusceptible *Streptococcus pneumoniae* in Tehran. *Microb Drug Resist*. 2019;25(6):865-73.
51. Mirzaei Ghazikalayeh H, Moniri R, Moosavi SGA, Rezaei M, Yasini M, Valipour M. Serotyping, Antibiotic Susceptibility and Related Risk Factors Aspects of Nasopharyngeal Carriage of *Streptococcus pneumoniae* in Healthy School Students. *Iran J Public Health*. 2014;43(9):1284-90.
52. Mehrabi Tavana A, Ataee RA, Najde Gerami EH, Goya MM, Rahbar M. Serotyping of clininical isolates of *Streptococcus pneumoniae* from Tehran, Iran. *Iran J Med Microbiol*. 2009;2(3-4):67-72. [In Persian]
53. Ortqvist A, Hedlund J, Kalin M. *Streptococcus pneumoniae*: epidemiology, risk factors, and clinical features. *Semin Respir Crit Care Med*. 2005;26(6):563-74.
54. Singh J, Sundaresan S, Manoharan A, Shet A. Serotype distribution and antimicrobial susceptibility pattern in children ≤ 5 years with invasive pneumococcal disease in India—A systematic review. *Vaccine*. 2017 16;35(35 Pt B):4501-9.

55. Zhao C, Xie Y, Zhang F, Wang Z, Yang S, Wang Q, et al. Investigation of Antibiotic Resistance, Serotype Distribution, and Genetic Characteristics of 164 Invasive *Streptococcus pneumoniae* from North China Between April 2016 and October 2017. *Infect Drug Resist*. 2020;13:2117-28.
56. Morais V, Texeira E, Suarez N. Next-generation whole-cell pneumococcal vaccine. *Vaccines (Basel)*. 2019;7(4):151.
57. Iroh Tam P-Y, Thielen BK, Obaro SK, Brearley AM, Kaizer AM, Chu H, et al. Childhood pneumococcal disease in Africa - A systematic review and meta-analysis of incidence, serotype distribution, and antimicrobial susceptibility. *Vaccine*. 2017;35(15):1817-27.
58. Hu J, Sun X, Huang Z, Wagner AL, Carlson B, Yang J, et al. *Streptococcus pneumoniae* and *Haemophilus influenzae* type b carriage in Chinese children aged 12-18 months in Shanghai, China: a cross-sectional study. *BMC Infect Dis*. 2016;16:149.
59. Song J-H, Jung S-I, Ko KS, Kim NY, Son JS, Chang H-H, et al. High prevalence of antimicrobial resistance among clinical *Streptococcus pneumoniae* isolates in Asia (an ANSORP study). *Antimicrob Agents Chemother*. 2004;48(6):2101-7.
60. Jain S, Williams DJ, Arnold SR, Ampofo K, Bramley AM, Reed C, et al. Community-acquired pneumonia requiring hospitalization among U.S. children. *N Engl J Med*. 2015;372(9):835-45.
61. Cilloniz C, Rodriguez-Hurtado D, Torres A. Characteristics and Management of Community-Acquired Pneumonia in the Era of Global Aging. *Med Sci (Basel)*. 2018;6(2):35.
62. Edmond K, Clark A, Korczak VS, Sanderson C, Griffiths UK, Rudan I. Global and regional risk of disabling sequelae from bacterial meningitis: a systematic review and meta-analysis. *Lancet Infect Dis*. 2010;10(5):317-28.
63. Wyllie AL, Chu ML, Schellens MH, van Engelsdorp Gastelaars J, Jansen MD, van der Ende A, et al. *Streptococcus pneumoniae* in saliva of Dutch primary school children. *PLoS One*. 2014;9(7):e102045.
64. Lopez B, Cima MD, Vazquez F, Fenoll A, Gutierrez J, Fidalgo C, et al. Epidemiological study of *Streptococcus pneumoniae* carriers in healthy primary-school children. *Eur J Clin Microbiol*. 1999;18(11):771-6.
65. Ahangarzadeh Rezaee M, Abdinia B, Delpak A, Rezamand A. The Microbiologic Pattern in Pediatric Cancer Patients with Febrile Neutropenia and Bacteremia: A Referral Hospital-Based Study in Northwest of Iran. *Iran J Pediatr*. 2017;27(2):e9452.
66. Kim SH, Song J-H, Chung DR, Thamlikitkul V, Yang Y, Wang H, et al. Changing trends in antimicrobial resistance and serotypes of *Streptococcus pneumoniae* isolates in Asian countries: an Asian Network for Surveillance of Resistant Pathogens (ANSORP) study. *Antimicrob Agents Chemother*. 2012;56(3):1418-26.
67. Mirnejad R, Jeddi F, Kiani J, Khoobdel M. Etiology of spontaneous bacterial peritonitis and determination of their antibiotic susceptibility patterns in Iran. *Asian Pac J Trop Dis*. 2011;1(2):116-8.